ATE175244T1 - Verfahren zur unterscheidung zwischen den varianten des menschlichen immunschwächevirus, die syncytien induzieren, und denen, die keine syncytien induzieren und primers zur verwendung in den verfahren - Google Patents
Verfahren zur unterscheidung zwischen den varianten des menschlichen immunschwächevirus, die syncytien induzieren, und denen, die keine syncytien induzieren und primers zur verwendung in den verfahrenInfo
- Publication number
- ATE175244T1 ATE175244T1 AT95914583T AT95914583T ATE175244T1 AT E175244 T1 ATE175244 T1 AT E175244T1 AT 95914583 T AT95914583 T AT 95914583T AT 95914583 T AT95914583 T AT 95914583T AT E175244 T1 ATE175244 T1 AT E175244T1
- Authority
- AT
- Austria
- Prior art keywords
- syncytias
- induce
- hiv
- primers
- differentiation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
- 230000004069 differentiation Effects 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 3
- 238000009396 hybridization Methods 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 108091027305 Heteroduplex Proteins 0.000 abstract 1
- 238000000636 Northern blotting Methods 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000002105 Southern blotting Methods 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000012620 biological material Substances 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 238000007901 in situ hybridization Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94201076 | 1994-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE175244T1 true ATE175244T1 (de) | 1999-01-15 |
Family
ID=8216813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95914583T ATE175244T1 (de) | 1994-04-19 | 1995-04-19 | Verfahren zur unterscheidung zwischen den varianten des menschlichen immunschwächevirus, die syncytien induzieren, und denen, die keine syncytien induzieren und primers zur verwendung in den verfahren |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6379881B1 (de) |
| EP (1) | EP0756639B1 (de) |
| JP (1) | JPH09511905A (de) |
| AT (1) | ATE175244T1 (de) |
| AU (1) | AU694205B2 (de) |
| CA (1) | CA2188317A1 (de) |
| DE (1) | DE69507022T2 (de) |
| DK (1) | DK0756639T3 (de) |
| ES (1) | ES2129199T3 (de) |
| GR (1) | GR3029671T3 (de) |
| WO (1) | WO1995028500A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1524088B (zh) | 2001-01-19 | 2012-11-07 | 维洛诺瓦蒂夫公司 | 在易感哺乳动物中引起呼吸道疾病的病毒 |
| TWI405851B (zh) | 2002-02-21 | 2013-08-21 | Medimmune Llc | 間質肺病毒株及其作為疫苗調配物及作為表現抗原性序列之載體之應用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US5604099A (en) * | 1986-03-13 | 1997-02-18 | Hoffmann-La Roche Inc. | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| GB8918226D0 (en) * | 1989-08-09 | 1989-09-20 | Wellcome Found | Dna assays |
-
1995
- 1995-04-19 AU AU21500/95A patent/AU694205B2/en not_active Ceased
- 1995-04-19 JP JP7526881A patent/JPH09511905A/ja not_active Ceased
- 1995-04-19 DE DE69507022T patent/DE69507022T2/de not_active Expired - Fee Related
- 1995-04-19 DK DK95914583T patent/DK0756639T3/da active
- 1995-04-19 AT AT95914583T patent/ATE175244T1/de not_active IP Right Cessation
- 1995-04-19 ES ES95914583T patent/ES2129199T3/es not_active Expired - Lifetime
- 1995-04-19 EP EP95914583A patent/EP0756639B1/de not_active Expired - Lifetime
- 1995-04-19 WO PCT/NL1995/000142 patent/WO1995028500A1/en not_active Ceased
- 1995-04-19 CA CA002188317A patent/CA2188317A1/en not_active Abandoned
-
1996
- 1996-04-19 US US08/722,015 patent/US6379881B1/en not_active Expired - Fee Related
-
1999
- 1999-03-12 GR GR990400755T patent/GR3029671T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GR3029671T3 (en) | 1999-06-30 |
| US6379881B1 (en) | 2002-04-30 |
| CA2188317A1 (en) | 1995-10-26 |
| DE69507022D1 (de) | 1999-02-11 |
| WO1995028500A1 (en) | 1995-10-26 |
| ES2129199T3 (es) | 1999-06-01 |
| EP0756639A1 (de) | 1997-02-05 |
| JPH09511905A (ja) | 1997-12-02 |
| DE69507022T2 (de) | 1999-06-24 |
| EP0756639B1 (de) | 1998-12-30 |
| AU694205B2 (en) | 1998-07-16 |
| DK0756639T3 (da) | 1999-08-30 |
| AU2150095A (en) | 1995-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hazan et al. | Autosomal dominant familial spastic paraplegia is genetically heterogeneous and one locus maps to chromosome 14q | |
| ES2118593T3 (es) | Analogos de nucleotidos de pteridina como sondas fluorescentes de adn. | |
| DE60038993D1 (de) | Oligonukleotidprimer zur reversen Transkription für den effizienten Nachweis von HIV-1 und HIV-2 und Methoden ihrer Verwendung | |
| GR3005272T3 (de) | ||
| PT81156B (pt) | Processo para a preparacao de uma sonda para a deteccao do adn de umvirus de linfadenocitos | |
| CY1108716T1 (el) | Μεθοδος διαγνωσεως της νοσου του alzheimer με βαση μια μορφη μεταγραφης γονιδιου. | |
| DE3850055D1 (de) | Mittel und Verfahren zur Erhöhung der Nukleinsäure-Hybridisierung. | |
| SE8801070D0 (sv) | Method for immobilizing a dna sequence on a solid support | |
| WO2000051055A3 (en) | Method and apparatus for monitoring therapy effectiveness | |
| DE69937055D1 (de) | Methode zur produktion oder verstärkung einer t-zell antwort gegen eine zielzelle durch verwendung eines komplexes aus einem hla klasse i moleküls und einer vorrichtung zum anheften | |
| ATE175244T1 (de) | Verfahren zur unterscheidung zwischen den varianten des menschlichen immunschwächevirus, die syncytien induzieren, und denen, die keine syncytien induzieren und primers zur verwendung in den verfahren | |
| ES2123000T3 (es) | Secuencias de adn del papilomavirus hpv 42 y su aplicacion en diagnostico. | |
| ES2069626T3 (es) | Sondas de dna especificas de neisseria. | |
| Steube et al. | A simple method using β-globin polymerase chain reaction for the species identification of animal cell lines—a progress report | |
| ATE213279T1 (de) | Diagnoseverfahren und vorrichtung zum nachweis der prädisposition zu bestimmten krankheitszuständen, insbesondere osteoporose, auf basis von il-6 genpolymorphismus | |
| DE60018926T2 (de) | "cort"-pcr assay zur unterscheidung von endogener reversen transkriptase aktivität in eukaryontischen zellen von einer kontamination durch infektiöse retroviren | |
| Borenshtain et al. | Marek's disease virus genome separation from feather tip extracts by pulsed field gel electrophoresis | |
| Samoszuk et al. | Epstein-Barr virus and interleukin-5 mRNA in acquired immunodeficiency syndrome-related lymphomas with eosinophilia | |
| ATE335806T1 (de) | Diagnosisverfahren für whipples krankheit | |
| EP1770100A3 (de) | Transferrin-Rezeptor Gene von Moraxella | |
| Gabal et al. | A polymerase chain reaction ‘PCR’for a quick diagnosis of aspergillosis | |
| ATE197965T1 (de) | Nukleinsäuresonde spezifisch für den spirochaeten borrelia burgdorferi | |
| Smart | Variations in viral load still under investigation | |
| Bricker et al. | Diagnostic assay for bacteria based on fragment amplification using insertion sequence location | |
| Sugihara et al. | 5-04-07 Activities of cathepsins B and L in peripheral blood of patients with human T-lymphotrophic virus type 1 (HTLV-1)-associated myelopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEFA | Change of the company name | ||
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |